Dried blood spots (DBS) are an alternative method of collecting venous blood samples that can be used to measure blood biomarkers. Two confounding factors, hemoglobin and hematocrit, limit the validity of DBS in comparison to the gold standard serum sample. The saturation of biomarkers on DBS filter paper is affected by the sample’s hematocrit and hemoglobin. Also hemoglobin contamination is known to confounder for antibody binding in assay systems. The purpose of this study was two-fold: 1) to evaluate a DBS punching technique designed to limit the effects of hematocrit whilst minimizing sample volume and 2) to evaluate a novel device designed to remove hemoglobin from plasma during DBS collection (Seraform™). A bead-based multiplex assay of nine cardiovascular disease risk (CVD) biomarkers (C-reactive protein, fibrinogen, L-selectin, Haptoglobin, serum amyloid protein, von Willebrand factor, adipsin, α2-macroglobulin, and α1-acid glycoprotein) was measured and compared using the various DBS treatments. Outcomes were compared using linear regression analysis examining the R2 change with hematocrit and hemoglobin as covariates. Significance was set at P



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.